Adenovirus Expression Vector Kit (Dual Version)
Total Page:16
File Type:pdf, Size:1020Kb
Ver.0.90 Code No. 6170 Adenovirus Expression Vector Kit (Dual Version) - 1 - Ver.0.90 Precautions for the use of this product ・ Please follow the guideline for experiments using recombinant DNA issued by the relevant authorities and the safety committee of your organization or your country in using this product. ・ The use of this product is limited for research purposes. It must not be used for clinical purposes or for in vitro diagnosis. ・ Individual license agreement must be concluded when this product is used for industrial purposes. ・ In this kit, recombinant viral particles infectious to mammalian cells are produced in 293 cells. Although this recombinant virus cannot proliferate in cells other than 293 cells, in case that it attaches to the skin or the airway, it efficiently enters cells and expresses the target gene. Please use a safety cabinet to prevent inhalation or adhesion of the virus. ・ Basic techniques of genetic engineering and cell cultivation are needed for the use of this product. ・ The user is strongly advised not to generate recombinant adenovirus capable of expressing known oncogenes and any genes known to be hazardous to the mammals. ・ Takara is not liable for any accident or damage caused by the use of this product. - 2 - Ver.0.90 Table of ContentsContents ⅠⅠ.. Introduction Ⅰ-1. Adenovirus vectors ……………………………………….…………………... 5 Ⅰ-2. Product overview ……………………………………………………………... 5 ⅡⅡ.. General Information …………………………………………………………….. 7 ■ For Adenovirus Expression Vector Kit (previous version) users …..……………… 8 ⅢⅢ.. Principles of recombinant adenovirus preparation Ⅲ-1. Full-length DNA transfer method ………………………………......... 9 Ⅲ-2. COS-TPC method ……………………………................................…...... 9 ⅣⅣ.. Content of the kit Ⅳ-1. Kit Component ……………………………………………… 12 Ⅳ-2. Cosmid vector structures ……………………………………………………… 13 ⅤⅤ.. Instruments and reagents required other than the kit Ⅴ-1. Instruments and equipments ……………………………………………….. 16 Ⅴ-2. Reagents ………………………………………………………………………… 16 ⅥⅥ.. Overview of Protocol <Importance of virus isolation> …………………………..……………... 18 <Control experiment> ……………………………………………………… 19 ⅦⅦ.. Procedure A. Construction and Preparation of the recombinant cosmid ………………. 19 A-1. Insertion of the target DNA into the cosmid vector …………………… 20 A-2. Confirmation of the structure of the recombinant cosmid ……………. 21 A-3. Large-scale preparation of the recombinant cosmid ………………….. 22 B. Generation and Confirmation of the recombinant adenovirus…………….. 23 B-1. Generation of the Recombinant adenovirus ……………………………. 23 <1> Full-length DNA transfer method ……………………………………. 23 <2> COS-TPC method ………………………………………………………. 26 B-2. Confirmation of the recombinant adenovirus ………………………….. 27 C. Preparation of high-titer recombinant adenovirus …………………………. 29 D. Viral titration [50% Tissue Culture Infectious Dose (TCID50)method] ……………………………………………………………………………………… 31 E. Infection of target cells with the virus ………………………………………… 32 - 3 - Ver.0.90 ⅧⅧ..Q&A. Q1. How should I choose a recombinant virus preparation method? ……….. 33 Q2. Is it necessary to confirm expression of the recombinant cosmid, and if so, how? ………………………………………………………………………………….…….. 34 Q3. Is the virus isolation step necessary with the full-length DNA transfer method? ……………………………………………………………………………………….. 35 Q4. No recombinant viruses appear. Why is it? …………………………………… 35 Q5. Why are the numbers of primary viruses obtained so low in comparison with the controls?………………………………………………………….…. 35 Q6. Why was cell degeneration observed in all wells? …………………………… 36 Q7. The titer of the virus does not increase. Why? …………………………….… 36 Q8. To what degree should the vector be diluted when it is infected to cells? ………………………………………………………………………………………… 36 Q9. How long does the expresstion last? ………………………………………… 37 Q10. What guidelines of the relevant authorities should be applied for experiments using recombinant DNA? ………………………………………………… 37 Q11. Is there potential for RCA contamination during passaging in 293 cells? ……………………………………………………………………………..……….. 38 Q12. If contamination occurs, how infective is the virus? ……………………… 39 Q13. How should disinfection be made in case of contamination (e.g In case that the medium is spilled)? …………………………………………………………... 39 ⅨⅨ..Related Products & Description of Service ……………………………………... 40 ⅩⅩ..Note ………………………………………………………………………………………40 ⅪⅪ..Appendixes Appendix 1. 293 cells ……………………………………………………………….. 40 Appendix 2. Handling of recombinant adenoviruses ………………………….. 43 Appendix 3. Definition of level P2 ……………………………………….……….. 44 Appendix 4. Large-scale recombinant adenovirus preparation…………………. 45 Appendix 5. Recombinant adenoviruses purification …………………………. 46 Appendix 6. RCA screening <PCR method> ………………………….………... 49 Appendix 7. Structure of adenovirus Ad5/dIX, and the recombinant virus.…………… 52 ⅫⅫ..Reference …………………………………………………………………………… 54 - 4 - Ver.0.90 I. Introduction I-1. Adenovirus vectors Adenovirus vectors are widely used as versatile expression vectors in various areas ranging from basic research to actual applications including functional analysis in animals as well as in cultured cells, because of their high utility and the other advantages listed below. (1) A high-titer virus can be obtained. Virus solution of 108 - 109 pfu/ml can be obtained with ease. They can further be concentrated to about 1011 pfu/ml. For this reason, it can transfer the target gene to nearly 100% of adherent cells. (2) It can be used in a wide range of animals. (3) It can infect resting cells as well as proliferating cells and express the target gene. (4) It can be targeted to a number of differentiated and undifferentiated cultured animal cells including the nervous system cells, and it can induce gene expression by direct infusion or administration to animal bodies. The adenovirus vectors most commonly used today are produced from human adenovirus serotype 5 (Ad5) with the E1 and E3 genes deleted. The E1 deletion renders these recombinant adenoviruses defective for replication in normal cells; they can only replicate in 293 cells (human embryonic kidney derived established cell line)1), which express the E1 gene. The E3 gene is not essential for viral replication in vitro; it is known to be associated with immune surveillance in vivo. The Adenovirus Expression Vector Kit (Dual Version) allows production of standard Ad5-derived recombinant adenoviruses with E1 and E3 deletions. These recombinant adenoviruses are defective for replication and can replicate only in 293 cells since they lack the E1 gene. These adenovirus vectors allow for the insertion of up to 7 kbp of foreign DNA. I-2. Product overview The Adenovirus Expression Vector Kit (Dual Version) is a kit that allows recombinant adenovirus production by either of two methods: the full-length DNA transfer method or the COS-TPC method 2). The COS-TPC method, developed by Dr. Saito and colleagues of the Institute of Medical - 5 - Ver.0.90 Science at the University of Tokyo, is a highly efficient technique for recombinant adenovirus production. The method was formerly available commercially as the Adenovirus Expression Vector Kit (TaKaRa Code 6150; discontinued) and has been used successfully by many researchers. The dual cosmid contained in this new Adenovirus Expression Vector Kit (Dual Version) (TaKaRa Code 6170) is a modified version of the former COS-TPC cosmid vector, and contains the complete adenovirus genome except for the E1 and E3 genes and was developed by the same group. This cosmid vector allows recombinant adenovirus production by either the full-length DNA transfer method or the COS-TPC method. With the full-length DNA transfer method, recombinant adenoviruses are produced only with recombinant cosmids created by insertion of the target gene into dual cosmids. This method is based on a particular principle; i.e., when plasmids containing a full-length adenovirus genome are transfected into 293 cells, viruses are only formed from plasmids cleaved by restriction enzymes at sites immediately flanking the viral genome termini 3). When it is difficult to product the recombinant virus using this method due to the characteristics of the inserted gene and other factors, the efficiency of virus production may be increased through the use of the COS-TPC method, i.e., co-transfection of recombinant cosmids and Adenovirus genome DNA-TPC (TaKaRa Code 6171; sold separately) into 293 cells. There are no differences in the structures or characteristics of recombinant viruses produced by either method. ⅡⅡ.. General Information About this kit, Recombinant adenoviruses are produced by the outline show below. See section VII. Procedure for detailed protocol. Outline of the generation of recombinant adenovirus A. Preparation of the recombinant cosmid. Insertion of the target gene into the cosmid vector, and prepare the recombinant cosmid. B. Generation of recombinant adenovirus. Transfect the recombinant cosmid prepared in A. into 293 cells and generate the recombinant adenovirus. C. Preparation of highhigh---titertiter rerecombinantcombinant adenovirus. Prepare large-scale recombinant adenovirus with a viral titer of 109 PFU/ml. - 6 - Ver.0.90 <1> Selection of cosmid vectors A. Select a cosmid vector based on the characteristics of the insert DNA and the purpose of the experiment prior to the start of recombinant cosmid preparation. See section IV-2. Cosmid vector structures for detailed information on cosmid vectors. • pAxCAwtit: suitable for high-level expression in a broad range of cell types The pAxCAwtit vector allows